FDA Grants Approval of Zymeworks and Jazz Pharmaceutical’s Ziihera for Previously Treated, Unresectable or Metastatic HER2-positive Biliary Tract Cancer

The FDA has approved Ziihera, a bispecific antibody developed by Zymeworks and Jazz Pharmaceuticals, for the treatment of HER2-positive biliary tract cancer. Ziihera’s unique binding profile enables multiple mechanisms of action, including dual blockade of HER2 signaling and removal of HER2 proteins from the surface of cancer cells. Additionally, the bispecific antibody enhances the immune system’s anti-cancer activity.